Centers for Medical Countermeasures Against Radiation

摘要 与过去相比，对全球核战争的担忧不太可能发生，取而代之的是一种真正的潜在的 使用放射性武器的恐怖袭击。近年来，此类袭击的威胁有所增加， 全球恐怖组织活动增加，非法贩运放射性材料增加。 不幸的是，很少有医疗产品可以对抗各种急性和长期毒性。 核攻击或辐射攻击造成的。仍然非常需要扩大现有的医疗选择 预防或治疗辐射损伤。我们成立了一个名为“辐射对策”的联盟 卓越研究中心(RadCCORE)集体协作增加可能的代理 检测、减轻和治疗那些暴露在确定剂量辐射下的人(www.radccore.org/)。 辐射生物学、健康物理学、干细胞生物学/移植和 免疫学已经走到了一起，形成了最全面、最包容、最跨机构和 辐射医学对策跨学科中心(CMCR)RadCCORE是一个 学术医疗中心：杜克大学、北卡罗来纳大学、维克森林大学和威尔 由四个研究项目和四个支助核心组成。这组调查人员的一个主要好处是 是个人在正常组织损伤、辐射生物学、 物理、培训和教育。考虑到我们的大多数先导化合物都是通过 开发流水线和现在都是外部资金，我们选择了一套新的有希望的 对策。这种安排带来了新的研究人员，增加了基础科学和翻译科学 知识和新颖的缓解剂送到我们的中心。该网络涉及广泛的研究领域，并已取得 在开发新的治疗产品以防止短期和长期毒性方面取得了长足进步。

Summary Concerns about global nuclear war, less likely than in the past, have been replaced by the real potential of a terrorist strike using radiological weapons. The threat of such attacks has grown in recent years, with the increased activity of global terrorist organizations and a rise in illicit trafficking of radioactive materials. Unfortunately, very few medical products exist to counter the variety of acute and long-term toxicities that can result from nuclear or radiological attacks. There remains a great need to expand the medical options available to prevent or treat radiation-induced injury. We have formed a consortium termed Radiation Countermeasures Centers of Research Excellence (RadCCORE) to collectively and collaboratively increase possible agents to detect, mitigate and treat those people exposed to deterministic doses of radiation (www.radccore.org/). Leading scientists in the area of radiation biology, health physics, stem cell biology/transplantation and immunology have come together to form one of the most comprehensive, inclusive, inter-institutional, and interdisciplinary Center for Medical Countermeasures Against Radiation (CMCR). RadCCORE is a network of academic medical centers: Duke University, University of North Carolina, and Wake Forest University and will consist of four research projects and four support cores. A major benefit of this group of investigators has been the dedication and strength of the individuals in the areas of normal tissue injury, radiation biology, physics, training and education. Given that most of our lead compounds have progressed through the development pipeline and are now externally funded, we have selected a new set of promising countermeasures. This arrangement brings novel investigators, increased basic and translational science knowledge and novel mitigators to our center. This network addresses broad areas of research and has made great strides in the development of new therapeutic products to prevent short- and long-term toxicities.